The Living Guidelines: UA/NSTEMI Recomendations for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy View the Current CLASS IIa Guidelines


 * CLASS IIa

1. For UA/NSTEMI patients in whom PCI is selected as a postangiography management strategy, it is reasonable to omit administration of an intravenous GP IIb/IIIa antagonist if bivalirudin was selected as the anticoagulant and at least 300 mg of clopidogrel was administered at least 6 h earlier. (Level of Evidence: B)

 Additional Management Considerations for Antiplatelet and Anticoagulant Therapy CLASS Ila Recommendation 1 should be: CLASS I CLASS IIa CLASS IIb CLASS III

2. If LVEF is less than or equal to 0.40, it is reasonable to perform diagnostic angiography. (Level of Evidence: B)

 Additional Management Considerations for Antiplatelet and Anticoagulant Therapy CLASS Ila Recommendation 2 should be: CLASS I CLASS IIa CLASS IIb CLASS III

3. If LVEF is greater than 0.40, it is reasonable to perform a stress test. (Level of Evidence: B)

 Additional Management Considerations for Antiplatelet and Anticoagulant Therapy CLASS Ila Recommendation 3 should be: CLASS I CLASS IIa CLASS IIb CLASS III